- Home
- NMRA vs LIEN Comparison
NMRA vs LIEN Comparison
Compare NMRA & LIEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- LIEN
- Stock Information
- Founded
- NMRA 2019
- LIEN 2021
- Country
- NMRA United States
- LIEN United States
- Employees
- NMRA N/A
- LIEN N/A
- Industry
- NMRA
- LIEN
- Sector
- NMRA
- LIEN
- Exchange
- NMRA Nasdaq
- LIEN NYSE
- Market Cap
- NMRA 287.6M
- LIEN 264.8M
- IPO Year
- NMRA 2023
- LIEN 2022
- Fundamental
- Price
- NMRA $1.16
- LIEN $11.36
- Analyst Decision
- NMRA Buy
- LIEN
- Analyst Count
- NMRA 8
- LIEN 0
- Target Price
- NMRA $10.14
- LIEN N/A
- AVG Volume (30 Days)
- NMRA 1.3M
- LIEN 10.3K
- Earning Date
- NMRA 03-03-2025
- LIEN 05-08-2025
- Dividend Yield
- NMRA N/A
- LIEN 12.03%
- EPS Growth
- NMRA N/A
- LIEN N/A
- EPS
- NMRA N/A
- LIEN 0.67
- Revenue
- NMRA N/A
- LIEN $12,681,914.00
- Revenue This Year
- NMRA N/A
- LIEN $71.81
- Revenue Next Year
- NMRA N/A
- LIEN $113.93
- P/E Ratio
- NMRA N/A
- LIEN $17.20
- Revenue Growth
- NMRA N/A
- LIEN 22.94
- 52 Week Low
- NMRA $1.13
- LIEN $8.38
- 52 Week High
- NMRA $17.19
- LIEN $13.38
- Technical
- Relative Strength Index (RSI)
- NMRA 28.13
- LIEN N/A
- Support Level
- NMRA $1.13
- LIEN N/A
- Resistance Level
- NMRA $1.48
- LIEN N/A
- Average True Range (ATR)
- NMRA 0.13
- LIEN 0.00
- MACD
- NMRA 0.06
- LIEN 0.00
- Stochastic Oscillator
- NMRA 17.03
- LIEN 0.00
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company's investment objective is to maximize risk-adjusted returns on equity for its stockholders by investing primarily in direct loans to privately held middle-market companies, with a focus on cannabis companies.